-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Benzinga·09/30/2026 14:47:50
Listen to the news
Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.